Australia TGA Classification Rule 5.5: Reclassification Changes for Medical Devices

Australia TGA Classification Rule 5.5: Reclassification Changes for Medical Devices

Australia's TGA has amended medical device classification rule 5.5, effective July 1, 2024. The change removes materials of microbial and recombinant origin from the scope of the rule, which previously mandated a Class III classification. This will lead to the down-classification of certain devices, such as some dermal fillers or surgical meshes, likely to Class IIb. Sponsors of existing devices on the ARTG must submit a reclassification application before the critical deadline of July 1, 2026, to continue supplying their products in Australia. Key Questions: - What specific changes did the TGA make to classification rule 5.5 on June 14, 2024? - How does this amendment affect medical devices containing materials of microbial or recombinant origin? - What is the new classification for devices that were previously Class III under this rule? - What is the critical deadline for sponsors of existing devices to apply for reclassification? - What happens if a sponsor misses the July 1, 2026 deadline? - Which types of medical devices are most likely to be impacted by this change? - What immediate steps should regulatory teams take to review their product portfolio? - How should manufacturers prepare their technical documentation for a reclassification submission to the TGA? Sources: - https://www.tga.gov.au/news/media-releases/medical-device-regulation-changes - https://regdesk.co/tga-notice-on-medical-device-regulations-change/ - https://www.tga.gov.au/resources/publication/regulatory-changes-medical-devices-containing-medicinal-substances-or-materials-animal-microbial-or-recombinant-origin How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We can help you navigate the TGA's reclassification requirements by developing a clear regulatory strategy, efficiently compiling your technical dossier using advanced AI, and managing your submission to ensure you meet the 2026 deadline. Our local experts in Australia provide in-country support, ensuring your transition is seamless and compliant. To learn how we can accelerate your market access, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

Switzerland's Swissdamed: Mandatory Device and IVD Registration by July 2026

Switzerland's swissdamed database becomes mandatory on July 1, 2026, for all medical devices and IVDs. This episode details the key deadlines, including the transition period until December 31, 2026, for existing devices, the scope of registration for all device classes, and the new annual fee structure based on UDI-DI counts. We provide practical steps for manufacturers to ensure compliance and maintain market access. Key Questions: - What is swissdamed and why is registration becoming mandatory? - What is the hard deadline for registering new medical devices in Switzerland? - Is there a grace period for devices already on the Swiss market? - Who is responsible for completing the swissdamed registration? - How will the new annual fees be calculated? - What data is required for a successful swissdamed submission? - How does swissdamed relate to the EU's EUDAMED database? - What are the immediate actions our regulatory team should take now? - How should we budget for these new Swiss compliance costs? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFj9gp0vO4-6LvYlKcwb2YLx5oYsv4udU7wWV5RGMQijyeuyyGacP979aRCUNg8bssHZSs6vd1NfYkaFUvspjkAqNBlqg2xyuyPnILyVWhYaDSE5C2b4HwR_lcyEfqpQrmzPPRX7T3l9VRZySTeEPClPEmFWIK-HkbhLrriOOt8DTBPfHmlAKtxbUsBluS5QQ== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpyNws7TRfcaaytmOBTsjujC-25m_XDthiKPR_Qod5ih2zZAV5LbnTzLX5F4lZ0i1gqSQ-GzaPhoSQOgk2h-TntvCwcGk2x1gOjPrSmDVV8HIy6jjhTlfQll2FCd2PCIzMX2JTFVg5uXWqa4IPu6XsD7-fSzBVQ7nfZftBkNhtA0Gpv8VfzHjpuMLQrPfVQtprTFU= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5I2yE-gMvSGEiPlzmItcVirtLhjd-t6612Xz6CwdxpHyrCZSnannSPtxDN4ikIur8Z3qSKphYrAxRBl8rHkM9Qads2CixbbJ7Hg6zeOBRSeG94Xk2_AE2oagFEZ9h7vxF2uCdJqXCpdgUrVcNcgETx-ibRrZWya8s5ihjAAns28UYW0KYZ1RvaF7OzB1IQroyTy23zG_vOdFZ0k6q8xjkY2d-LnYEBQ== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE98pavdxGcQG6Ak49uInD79TeOqkrV1lDWdk2pbr9yW3wQWVUeK1KbUZIU_6sgW51FJgxlRs9DnghJktdCdCQvztBik7qkz3haJXi1k7zrk1PoCMVDguL1UCHNRlLdI6ltH8Wk2nkC0e44i5PSGkUHJe6GvlNOAJ3rQanyVQPYLkZvYmAxOgw= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGBHa2TzL0KLOkrmDyEjM0qYQ0XjFMAJaW2lmhERdq7JvbdDcu7yEw58vSZXYX4VvMXGYwhKvJ6XiXpoH8RovfI3o1vQOIrqeAO5E8E2kHpppZ98UgEfap6DdVQPFtcbcGH3wdyieJtbQCQMVI2NZfthHxapjBUY8ezbPa88lcoA5biINZOI9E32K_2TUW2bNpweSknDW5kLJrS How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, ensuring you can navigate complex changes like the mandatory swissdamed registration. We act as your Swiss Authorized Representative (CH-REP), manage the entire registration process, and develop strategies to minimize costs and ensure uninterrupted market access. Our AI-powered tools and expert local teams help you efficiently compile technical dossiers and monitor regulatory changes, so you can focus on innovation. For expert support on your path to global compliance, visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

UK MHRA International Reliance: Navigating the Draft 2026 Medical Device Regulations

This episode details the UK MHRA's draft Medical Devices (Amendment) Regulations 2026, focusing on the proposed International Reliance pathway. We explore how this new framework aims to streamline market access in Great Britain for devices already approved by regulators in the US, Canada, or Australia. We cover the significance of the stakeholder survey deadline of June 19, 2026, the anticipated entry into force in June 2027, and the practical steps manufacturers should take now to prepare for this major regulatory shift. Key Questions: - What is the UK MHRA's proposed International Reliance pathway? - Which international approvals will be recognized for faster Great Britain market access? - What was the significance of the June 19, 2026, stakeholder survey deadline? - When are the new Medical Devices (Amendment) Regulations 2026 expected to come into force? - How does this proposal change the post-Brexit regulatory landscape for medical devices in the UK? - What types of devices will be eligible for this new pathway? - What practical steps should regulatory teams take now to prepare for these changes? - How will this impact manufacturers who only have a CE mark? - What documentation might be required even under the reliance framework? Sources: - https://www.pinsentmasons.com/out-law/analysis/update-to-the-medical-devices-regulatory-regime-key-proposals-and-implications - https://www.dacbeachcroft.com/en/gb/articles/2026/june/mhra-publishes-draft-regulations-for-medical-device-reform/ - https://www.arnoldporter.com/en/perspectives/publications/2026/05/mhra-publishes-draft-amendment-to-the-uk-medical-devices-regulations - https://www.jdsupra.com/legalnews/recent-eu-and-uk-medical-devices-8991557/ - https://www.gs1uk.org/news-research/news/mhra-draft-reforms-for-medical-device-regulation-in-great-britain How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex regulatory shifts like the UK's new International Reliance pathway. Our experts develop efficient market access strategies, act as your local UK Responsible Person, and use advanced AI to compile and manage technical submissions, ensuring you are prepared for the June 2027 changes. We help you leverage existing approvals to accelerate entry into new markets while maintaining compliance. For support with your global regulatory strategy, contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

Brazil ANVISA Regulatory Reliance: June 2024 Update to IN 290/2024 Streamlines Class III/IV Device Review

Brazil's ANVISA has updated its review process for the regulatory reliance pathway under IN 290/2024. As of mid-June 2024, instead of rejecting submissions with minor issues, the agency will now issue requirement notices, allowing manufacturers to amend their applications. This episode explains how this change de-risks the submission process for Class III and IV medical devices that rely on approvals from Australia, Canada, the U.S., or Japan, making the pathway more efficient and predictable. Key Questions: - What is Brazil's new regulatory reliance pathway under IN 290/2024? - How has ANVISA's review process for reliance submissions changed as of June 2024? - Why is this change significant for manufacturers of Class III and IV medical devices? - What were the risks of the reliance pathway before this update? - How does the new process of issuing requirement notices reduce submission risk? - Which foreign regulatory approvals are recognized by ANVISA for this pathway? - What practical steps should your regulatory team take to prepare a successful reliance submission? - How can you ensure your submission avoids triggering a requirement notice from ANVISA? Sources: - https://www.emergobyul.com/news/regulatory-reliance-authorizations-brazils-revised-anvisa-process-june-2026 - https://www.emergobyul.com/news/anvisa-updates-hospitalar-2026-attendees-about-regulatory-reliance How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying access to over 30 global markets, including Brazil. Our experts can help you develop an efficient regulatory strategy for the ANVISA reliance pathway, manage the technical dossier preparation, and act as your local representative to handle all communications with the agency, including responding to requirement notices. We combine local expertise with advanced AI to accelerate your submission and ensure compliance. For help with your market access strategy, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

China NMPA Post-Market Vigilance 2026: New Rules for Foreign Manufacturers

This episode provides a detailed analysis of China's NMPA new post-market vigilance framework, released on June 12, 2026. We discuss the mandatory, risk-based system that introduces new obligations for foreign medical device manufacturers, including detailed requirements for trend reporting, Periodic Safety Update Reports (PSURs), and comprehensive vigilance planning. Learn about the immediate compliance steps your company must take to maintain market access in China. Key Questions: - What are the key components of China's new post-market vigilance framework? - How does the NMPA's 2026 update affect overseas medical device manufacturers? - What are the new requirements for Periodic Safety Update Reports (PSURs) in China? - What is trend reporting and how must it be implemented under the new NMPA rules? - What specific actions should regulatory teams take to ensure compliance with these changes? - How does the risk-based approach change post-market surveillance obligations in China? - What is the role of the China Agent in this new vigilance system? - Are there immediate deadlines for implementing these new vigilance plans? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLsm9oWY0mwgxGjOzXpOhnX6mb_eSYMd2eJdGyRW0KTBfhCtttdPOeRD_8Nzyq12FBpBPa4wS6BUSh2s2v_RM1MEMGAW5cSZriDznF0Hal8q-yufaFLrzpxl-HiaKZ7gNmqblkfoIwzbba8Mf0L816TbpmNJLGIJzzqf6rbXvJCSw= How Pure Global can help: Navigating China's complex regulatory landscape requires local expertise and a proactive strategy. Pure Global provides end-to-end support for MedTech and IVD companies, from initial registration to post-market surveillance and vigilance compliance. Our in-country experts in China can act as your legal agent, help you develop an NMPA-compliant vigilance plan, and manage your reporting obligations. We leverage advanced AI tools to streamline dossier preparation and monitor regulatory changes, ensuring you maintain compliance and market access. Visit https://pureglobal.com or contact us at info@pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.